Guardant Health Licensing and other — Total Revenue decreased by 1.8% to $2.14M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.3%, from $1.86M to $2.14M. Over 2 years (FY 2023 to FY 2025), Licensing and other — Total Revenue shows a downward trend with a -39.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful monetization of intellectual property or growth in strategic partnerships, while a decrease may indicate expiring licenses or a shift in focus toward core diagnostic operations.
This metric represents the total revenue generated from non-core business activities, including the licensing of proprie...
Peers in the biotechnology and diagnostics space often report similar 'other' or 'licensing' revenue, which typically fluctuates based on the timing of milestone payments and the lifecycle of patent portfolios.
gh_segment_licensing_and_other_total_revenue| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.93M | $5.93M | $5.93M | $5.93M | $5.16M | $3.03M | $2.73M | $2.57M | $1.86M | $2.57M | $1.95M | $2.18M | $2.14M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -13.1% | -41.2% | -10.0% | -5.9% | -27.6% | +38.2% | -24.1% | +11.9% | -1.8% |
| YoY Change | — | — | — | — | -13.1% | -48.9% | -54.0% | -56.7% | -63.9% | -15.3% | -28.5% | -15.0% | +15.3% |